Novartis | NOVN - Cost Of Sales


Novartis reported $3.71B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Alcon AG USD 1.12B 61M Jun/2026
Almirall EUR 199.26M 7.76M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Autolus Therapeutics Ltd USD 24.57M 762K Mar/2026
Bayer EUR 4.54B 692M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Fresenius EUR 4.4B 111M Jun/2026
Fresenius Medical Care EUR 3.55B 117.58M Jun/2026
Genmab DKK 84M 19M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
GRIFOLS EUR 1.17B 90M Jun/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
J&J USD 8B 67M Jun/2026
Lakefront Biotherapeutics EUR 9.14M 4.35M Jun/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.27B 199M Jun/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Novo Nordisk DKK 17.1B 3.5B Jun/2026
Orion EUR 181.7M 18M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Philips EUR 2.21B 70M Jun/2026
Recordati EUR 199.38M 3.22M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
UCB EUR 1.07B 146M Dec/2025